Adaptive Biotechnologies Partners with Pfizer on $890 Million TCR Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy ADPT?
Source: Newsfilter
- Target Discovery Agreement: Adaptive Biotechnologies has signed an agreement with Pfizer to leverage its platform for identifying disease-specific T-cell receptors (TCRs) in rheumatoid arthritis patients, which is expected to accelerate Pfizer's therapeutic candidate development and enhance its competitiveness in autoimmune diseases.
- Data Licensing Agreement: Pfizer has licensed Adaptive's TCR-antigen datasets to develop AI models, accelerating research and drug discovery across multiple disease areas, thereby reinforcing Pfizer's technological edge in the biopharmaceutical sector.
- Potential Revenue: Under the RA agreement, Adaptive will receive an upfront payment and may earn up to $890 million in potential milestone payments, which not only strengthens the company's financial stability but also provides funding support for future R&D initiatives.
- Strategic Collaboration: This partnership signifies Adaptive's further expansion in the field of immune medicine, utilizing its advanced immune receptor data to drive the development of next-generation therapeutic solutions, showcasing the company's innovation capabilities and market potential in the biotechnology industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.540
Low
20.00
Averages
20.86
High
22.00
Current: 15.540
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adaptive Biotechnologies Reports Strong Q4 2025 Earnings Growth and Positive Outlook
- Significant Revenue Growth: Adaptive Biotechnologies reported Q4 2025 revenue of $71.7 million, a 63% year-over-year increase, with the MRD segment contributing $61.9 million, reflecting strong market performance and sustained growth potential.
- Profitability Achieved Ahead of Schedule: The company achieved full-year revenue of $277 million, up 55% year-over-year, and reported adjusted EBITDA of $4.1 million in Q4, a substantial improvement from a $16.4 million loss a year ago, indicating success in cost control and operational efficiency.
- Optimistic Future Outlook: Management expects clonoSEQ test volumes to grow over 30% year-over-year in 2026, targeting MRD revenue between $255 million and $265 million, demonstrating confidence in market demand and strategic execution.
- Strong Cash Position: By the end of 2025, the company had $227 million in cash and equivalents, with a 68% reduction in cash burn, providing a solid financial foundation for future investments and expansion.
See More
Adaptive Biotechnologies to Announce Q4 Earnings on February 5th
- Earnings Announcement: Adaptive Biotechnologies is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimated at -$0.18 and revenue expected to reach $60.9 million, reflecting a 28.3% year-over-year growth that underscores the company's ongoing growth potential in the biotech sector.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen two upward revisions and four downward adjustments, while revenue estimates have experienced two upward revisions and five downward adjustments, indicating market divergence regarding the company's future performance, which could impact investor confidence.
- Strong Industry Performance: Adaptive Biotechnologies has emerged as the top-performing stock in the life sciences tools and services sector year-to-date, demonstrating its competitive edge and market recognition within the industry.
- Key Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and within the industry, potentially paving the way for future financing and partnership opportunities.
See More
Adaptive Biotechnologies Reports 55% Revenue Growth to $277 Million for FY 2025
- Significant Revenue Growth: Adaptive Biotechnologies reported preliminary unaudited revenue of approximately $277 million for FY 2025, reflecting a robust 55% year-over-year increase, which is expected to bolster market confidence in the company's growth trajectory.
- Strong Q4 Performance: The company achieved approximately $72 million in revenue for Q4 2025, a 51% increase compared to the same quarter in 2024, with minimal residual disease (MRD) revenue reaching $62 million, indicating ongoing expansion in precision medicine.
- Testing Volume Surge: clonoSEQ testing volume surged by 43% in Q4 2025 to approximately 30,000 tests, with a total of about 105,600 tests delivered for the year, marking a 39% increase from 2024, showcasing rising market demand for this testing service.
- Robust Cash Reserves: As of December 31, 2025, the company reported approximately $227 million in cash, cash equivalents, and marketable securities, providing substantial flexibility for future investments and research and development initiatives.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
Adaptive Biotechnologies Reports $72M Q4 Revenue, 43% Increase in ClonoSEQ Tests
- Significant Revenue Growth: Adaptive Biotechnologies reported total revenue of $72 million in Q4 2025, with the MRD segment contributing approximately $62 million, marking a substantial increase from $47.5 million in Q4 2024, indicating strong performance in cancer diagnostics.
- Increased Test Volume: The clonoSEQ test volume reached 30,000 in Q4 2025, representing a 43% increase compared to Q4 2024, reflecting not only rising market demand but also the company's success in technology adoption.
- Annual Performance Review: For the full year 2025, total revenue was approximately $277 million, with MRD revenue contributing $212 million, significantly up from $179 million in 2024, showcasing the company's ongoing expansion and growing market recognition in immune medicine.
- Future Outlook: Adaptive Biotechnologies plans to release its complete Q4 and full year 2025 financial results in February 2026, which is expected to further bolster investor confidence and drive stock price appreciation.
See More
Adaptive Biotechnologies Reports 55% Revenue Growth to $277 Million in 2025
- Significant Revenue Growth: Adaptive Biotechnologies reported total revenue of approximately $277 million for 2025, reflecting a robust 55% increase over 2024, indicating strong performance and rising market demand in the biotechnology sector.
- Strong MRD Business: The MRD revenue reached $212 million in 2025, a 46% year-over-year increase, with fourth-quarter MRD revenue at $62 million, up 54%, underscoring the company's strengthening leadership in the minimal residual disease (MRD) testing market.
- Test Volume Surge: In the fourth quarter of 2025, clonoSEQ test volume surged to approximately 30,000 tests, a 43% increase compared to the same quarter in 2024, culminating in about 105,600 tests delivered for the year, up 39%, reflecting growing customer recognition and demand for the test.
- Strong Cash Reserves: As of December 31, 2025, Adaptive held approximately $227 million in cash and cash equivalents, providing robust financial support for future R&D and market expansion initiatives.
See More
Adaptive Biotechnologies Reports Strong Q4 2025 Earnings Growth and Positive Outlook
- Significant Revenue Growth: Adaptive Biotechnologies reported Q4 2025 revenue of $71.7 million, a 63% year-over-year increase, with the MRD segment contributing $61.9 million, reflecting strong market performance and sustained growth potential.
- Profitability Achieved Ahead of Schedule: The company achieved full-year revenue of $277 million, up 55% year-over-year, and reported adjusted EBITDA of $4.1 million in Q4, a substantial improvement from a $16.4 million loss a year ago, indicating success in cost control and operational efficiency.
- Optimistic Future Outlook: Management expects clonoSEQ test volumes to grow over 30% year-over-year in 2026, targeting MRD revenue between $255 million and $265 million, demonstrating confidence in market demand and strategic execution.
- Strong Cash Position: By the end of 2025, the company had $227 million in cash and equivalents, with a 68% reduction in cash burn, providing a solid financial foundation for future investments and expansion.
See More
Adaptive Biotechnologies to Announce Q4 Earnings on February 5th
- Earnings Announcement: Adaptive Biotechnologies is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimated at -$0.18 and revenue expected to reach $60.9 million, reflecting a 28.3% year-over-year growth that underscores the company's ongoing growth potential in the biotech sector.
- Earnings Estimate Fluctuations: Over the past three months, EPS estimates have seen two upward revisions and four downward adjustments, while revenue estimates have experienced two upward revisions and five downward adjustments, indicating market divergence regarding the company's future performance, which could impact investor confidence.
- Strong Industry Performance: Adaptive Biotechnologies has emerged as the top-performing stock in the life sciences tools and services sector year-to-date, demonstrating its competitive edge and market recognition within the industry.
- Key Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility among investors and within the industry, potentially paving the way for future financing and partnership opportunities.
See More
Adaptive Biotechnologies Reports 55% Revenue Growth to $277 Million for FY 2025
- Significant Revenue Growth: Adaptive Biotechnologies reported preliminary unaudited revenue of approximately $277 million for FY 2025, reflecting a robust 55% year-over-year increase, which is expected to bolster market confidence in the company's growth trajectory.
- Strong Q4 Performance: The company achieved approximately $72 million in revenue for Q4 2025, a 51% increase compared to the same quarter in 2024, with minimal residual disease (MRD) revenue reaching $62 million, indicating ongoing expansion in precision medicine.
- Testing Volume Surge: clonoSEQ testing volume surged by 43% in Q4 2025 to approximately 30,000 tests, with a total of about 105,600 tests delivered for the year, marking a 39% increase from 2024, showcasing rising market demand for this testing service.
- Robust Cash Reserves: As of December 31, 2025, the company reported approximately $227 million in cash, cash equivalents, and marketable securities, providing substantial flexibility for future investments and research and development initiatives.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
Adaptive Biotechnologies Reports $72M Q4 Revenue, 43% Increase in ClonoSEQ Tests
- Significant Revenue Growth: Adaptive Biotechnologies reported total revenue of $72 million in Q4 2025, with the MRD segment contributing approximately $62 million, marking a substantial increase from $47.5 million in Q4 2024, indicating strong performance in cancer diagnostics.
- Increased Test Volume: The clonoSEQ test volume reached 30,000 in Q4 2025, representing a 43% increase compared to Q4 2024, reflecting not only rising market demand but also the company's success in technology adoption.
- Annual Performance Review: For the full year 2025, total revenue was approximately $277 million, with MRD revenue contributing $212 million, significantly up from $179 million in 2024, showcasing the company's ongoing expansion and growing market recognition in immune medicine.
- Future Outlook: Adaptive Biotechnologies plans to release its complete Q4 and full year 2025 financial results in February 2026, which is expected to further bolster investor confidence and drive stock price appreciation.
See More
Adaptive Biotechnologies Reports 55% Revenue Growth to $277 Million in 2025
- Significant Revenue Growth: Adaptive Biotechnologies reported total revenue of approximately $277 million for 2025, reflecting a robust 55% increase over 2024, indicating strong performance and rising market demand in the biotechnology sector.
- Strong MRD Business: The MRD revenue reached $212 million in 2025, a 46% year-over-year increase, with fourth-quarter MRD revenue at $62 million, up 54%, underscoring the company's strengthening leadership in the minimal residual disease (MRD) testing market.
- Test Volume Surge: In the fourth quarter of 2025, clonoSEQ test volume surged to approximately 30,000 tests, a 43% increase compared to the same quarter in 2024, culminating in about 105,600 tests delivered for the year, up 39%, reflecting growing customer recognition and demand for the test.
- Strong Cash Reserves: As of December 31, 2025, Adaptive held approximately $227 million in cash and cash equivalents, providing robust financial support for future R&D and market expansion initiatives.
See More
